Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
4Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Protagenic Therapeutics, Inc. (PTIX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
4Distinct source URLs
5High confidence
0.765Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Protagenic Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
PHYTANIX-BIO
PHYTANIX-BIO
92%
PTIX agreed to pay Phytanix Bio $300,000 at Closing and an additional $10,000 following receipt of specified financial information, in accordance with the terms of the Unwind Agreement.
UNIVERSITY
UNIVERSITY
92%
On July 31, 2005, the Company had entered into a Technology License Agreement with the University pursuant to which the University agreed to license to the Company patent rights and other intellectua…
ats and non-human primates. The doses tested were substantially above the anticipated clinical doses and were well tolerated and safe, with no dose-limiting toxicities observed at doses at least 50-f…
Reciprocal relationship from JNJ graph: Reciprocal relationship from PTIX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from PTIX graph: Reciprocal relationship from JNJ grap…
Reciprocal relationship from PYPD graph: we have incurred over the last two years pursuant to our research and development programs, please see “Item 5. Operating and Financial Review and Prospects— …
Protagenic Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
ALINOVA-BIOSCIENCES-LTD
ALINOVA-BIOSCIENCES-LTD
62%
anies such as Apex Molecular Ltd. to synthesize and purify these compounds for their pharmaceutical development programs. ● Acquisition of intellectual property from Alinova Biosciences Ltd. ● Contin…
APEX-MOLECULAR-LTD
APEX-MOLECULAR-LTD
62%
anies such as Apex Molecular Ltd. to synthesize and purify these compounds for their pharmaceutical development programs. ● Acquisition of intellectual property from Alinova Biosciences Ltd. ● Contin…
BACKGROUND-PROTAGENIC-THERAPEUTICS-INC
BACKGROUND-PROTAGENIC-THERAPEUTICS-INC
62%
NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS Company Background Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”), formerly known as Atrinsic, Inc., is a Delaware corporation…
PROTEIN-TECHNOLOGIES-LTD
PROTEIN-TECHNOLOGIES-LTD
62%
sured at the end of each reporting period. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilitie…
Protagenic Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
PTIX-DEBT-11937
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2023-12-31.
PTIX-DEBT
Debt stack $4.0M
90%
Market cache reports total debt of $4.0M.
PTIX-DEBT-11936
Warrants outstanding: 81600
90%
xbrl warrant detail from xbrl 2025-12-31.
Protagenic Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Protagenic Therapeutics, Inc..
Protagenic Therapeutics, Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Protagenic Therapeutics, Inc..
Protagenic Therapeutics, Inc. Extended Supply Chain Network
